Decoy Therapeutics Inc.
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture pe… Read more
Decoy Therapeutics Inc. (DCOY) - Net Assets
Latest net assets as of September 2025: $4.25 Million USD
Based on the latest financial reports, Decoy Therapeutics Inc. (DCOY) has net assets worth $4.25 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.10 Million) and total liabilities ($1.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.25 Million |
| % of Total Assets | 69.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | -93.18% |
| 10-Year Change | -98.36% |
| Growth Volatility | 63.79 |
Decoy Therapeutics Inc. - Net Assets Trend (2014–2024)
This chart illustrates how Decoy Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Decoy Therapeutics Inc. (2014–2024)
The table below shows the annual net assets of Decoy Therapeutics Inc. from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.51 Million | -71.41% |
| 2023-12-31 | $5.29 Million | -49.09% |
| 2022-12-31 | $10.38 Million | -73.18% |
| 2021-12-31 | $38.72 Million | +74.75% |
| 2020-12-31 | $22.16 Million | +109.43% |
| 2019-12-31 | $10.58 Million | +13.99% |
| 2018-12-31 | $9.28 Million | -68.11% |
| 2017-12-31 | $29.11 Million | -50.93% |
| 2016-12-31 | $59.32 Million | -35.66% |
| 2015-12-31 | $92.19 Million | +1510.19% |
| 2014-12-31 | $-6.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Decoy Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7391275800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $144.00 | 0.01% |
| Other Components | $83.44 Million | 5519.31% |
| Total Equity | $1.51 Million | 100.00% |
Decoy Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Decoy Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DHTRF
PINK:DHTRF
|
$76.97K |
|
New Mountain Finance Corporation
NASDAQ:NMFC
|
$76.97K |
|
DAIWA SEC GRP - Dusseldorf Stock Exchang
DU:DSE
|
$77.08K |
|
Trustpilot Group PLC
LSE:TRST
|
$77.09K |
|
HELIX ENERGY SOLNS
MU:CTV
|
$76.95K |
|
ASURE SOFTWARE (VTE1.SG)
STU:VTE1
|
$76.78K |
|
TAKIX
NMFQS:TAKIX
|
$76.73K |
|
ENGI11F
SA:ENGI11F
|
$76.72K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Decoy Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,287,282 to 1,511,695, a change of -3,775,587 (-71.4%).
- Net loss of 5,575,777 reduced equity.
- New share issuances of 1,526,460 increased equity.
- Other factors increased equity by 273,730.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.58 Million | -368.84% |
| Share Issuances | $1.53 Million | +100.98% |
| Other Changes | $273.73K | +18.11% |
| Total Change | $- | -71.41% |
Book Value vs Market Value Analysis
This analysis compares Decoy Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.34x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-278331.20 | $8.08 | x |
| 2015-12-31 | $61286.73 | $8.08 | x |
| 2016-12-31 | $266355.57 | $8.08 | x |
| 2017-12-31 | $124939.42 | $8.08 | x |
| 2018-12-31 | $39847.00 | $8.08 | x |
| 2019-12-31 | $9663.06 | $8.08 | x |
| 2020-12-31 | $4246.01 | $8.08 | x |
| 2021-12-31 | $2794.36 | $8.08 | x |
| 2022-12-31 | $72.96 | $8.08 | x |
| 2023-12-31 | $24.17 | $8.08 | x |
| 2024-12-31 | $23.45 | $8.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Decoy Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -368.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.00x
- Recent ROE (-368.84%) is below the historical average (-135.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.36 Million |
| 2015 | -31.61% | 0.00% | 0.00x | 1.03x | $-38.36 Million |
| 2016 | -66.58% | -3907.65% | 0.02x | 1.07x | $-45.42 Million |
| 2017 | -118.30% | -2701.74% | 0.04x | 1.20x | $-37.34 Million |
| 2018 | -236.16% | -2615.57% | 0.08x | 1.12x | $-22.85 Million |
| 2019 | -65.55% | -200.18% | 0.25x | 1.31x | $-7.99 Million |
| 2020 | -33.18% | -140.49% | 0.21x | 1.13x | $-9.57 Million |
| 2021 | -32.97% | -693.84% | 0.05x | 1.05x | $-16.64 Million |
| 2022 | -304.37% | 0.00% | 0.00x | 1.41x | $-32.65 Million |
| 2023 | -237.22% | 0.00% | 0.00x | 1.25x | $-13.07 Million |
| 2024 | -368.84% | 0.00% | 0.00x | 2.00x | $-5.73 Million |
Industry Comparison
This section compares Decoy Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | $4.25 Million | 0.00% | 0.44x | $76.95K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |